Bank of New York Mellon’s Sagimet Biosciences SGMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.55M Buy
+200,648
New +$1.36M ﹤0.01% 3102
2024
Q2
Sell
-62,181
Closed -$337K 4244
2024
Q1
$337K Buy
62,181
+40,056
+181% +$288K ﹤0.01% 3730
2023
Q4
$120K Buy
22,125
+8,820
+66% +$41.6K ﹤0.01% 4056
2023
Q3
$117K Buy
+13,305
New +$177K ﹤0.01% 4061

Other funds holding SGMT

Bank of New York Mellon's SGMT Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 200,648 shares worth $1.55M. The stake represents ﹤0.01% of the portfolio and ranks #3102 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in SGMT as recently as Q1 2024.

Bank of New York Mellon first reported a position in SGMT in Q3 2023 and has held it in 4 quarters since. 49 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Bank of New York Mellon held 200,648 shares of Sagimet Biosciences worth $1.55M as of Q2 2026.
  • Sagimet Biosciences was a new Bank of New York Mellon position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3102 holding.
  • Bank of New York Mellon first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 4 quarters since.
  • 49 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.